A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.
Inclusion Criteria:
Exclusion Criteria:
Edina, Minnesota 55435, United States
Salt Lake City, Utah 84132, United States
CABA, C1017AAO, Argentina
Capital Federal, C1120AAN, Argentina
Vienna, 1090, Austria
Dresden, 01307, Germany
Homburg/Saar, 66424, Germany
Rome, Lazio 00198, Italy
Milan, Lombardy 20100, Italy
Pisa, Tuscany 56124, Italy
Perugia, Umbria 06129, Italy
Negrar - Verona, Veneto 37024, Italy
Hokkaido, 060-8648, Japan
Hokkaido, 078-8510, Japan
Del. Cuauhtemoc, Mexico CITY (federal District) 06760, Mexico
Krakow, 31-501, Poland
Cheboksary, Mariy-El Republic 428000, Russia
Moscow, Moscow Oblast 119435, Russia
Irkutsk, 664033, Russia
Novosibirsk, 630096, Russia
Santiago de Compostela, LA Coruña 15706, Spain
Las Palmas de Gran Canaria, LAS Palmas 35016, Spain
Oviedo, Principality of Asturias 33012, Spain
Zhongzheng Dist., 10002, Taiwan
Ankara, 06490, Turkey (Türkiye)
Istanbul, 34421, Turkey (Türkiye)
Great Yarmouth, Norfolk NR31 6LA, United Kingdom
Liverpool, L7 8YE, United Kingdom
Southampton, SO16 6YD, United Kingdom